search
Back to results

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Fluticasone propionate/formoterol fumarate
Sponsored by
SkyePharma AG
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, Fluticasone Propionate, Formoterol Fumarate, Pressurized metered does inhaler, Hydrofluoroalkane, Mild to moderate-severe asthma

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Ages eligible for study: 12 years and above; genders eligible for study: both; prior steroid use: steroid-requiring.

Inclusion Criteria:

  • History of asthma for at least 12 months.
  • Documented use of inhaled corticosteriod for at least 4 weeks prior to Screening Visit Demonstrate FEV-1 of 40-80% of predicted normal values at Screening and Baseline Visit.
  • Documented reversibility of 15% within 6 months of Screening Visit or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation).
  • Symptoms of Asthma during Run-in.
  • Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating and are either sterile or using acceptable methods of contraception.
  • Must otherwise be healthy.
  • Provide written informed consent. Wishes of minors must be respected.

Exclusion Criteria:

  • Life-threatening asthma within past year or during Run-in Period.
  • History of systemic corticosteroid medication within 3 months before Screening Visit.
  • History of omalizumab use within the past 6 months.
  • History of leukotriene receptor antagonist use, e.g., montelukast, within the past week.
  • Current evidence of history of any clinically significant disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.
  • Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-in Period.
  • Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease [COPD], cystic fibrosis, bronchiectasis).
  • Known Human Immunodeficiency Virus (HIV)-positive status.
  • Smoking history equivalent to "10 pack years".
  • Current smoking history within 12 months prior to Screening Visit.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Outcomes

Primary Outcome Measures

Long-term safety after twice daily treatment with FlutiForm HFA MDI over 12 months.

Secondary Outcome Measures

Long-term efficacy after twice daily treatment with FlutiForm HFA MDI over 12 months.

Full Information

First Posted
October 27, 2006
Last Updated
August 24, 2010
Sponsor
SkyePharma AG
search

1. Study Identification

Unique Protocol Identification Number
NCT00394121
Brief Title
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
Official Title
Long-term Open-label Safety Study With SkyePharma FlutiForm HFA pMDI (100/10 µg and 250/10 µg) in Adult and Adolescent Patients With Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
August 2010
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
July 2007 (Actual)
Study Completion Date
July 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
SkyePharma AG

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to evaluate the long-term safety of the fixed combination asthma drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult and adolescent patients with mild to moderate-severe asthma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Fluticasone Propionate, Formoterol Fumarate, Pressurized metered does inhaler, Hydrofluoroalkane, Mild to moderate-severe asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Fluticasone propionate/formoterol fumarate
Primary Outcome Measure Information:
Title
Long-term safety after twice daily treatment with FlutiForm HFA MDI over 12 months.
Secondary Outcome Measure Information:
Title
Long-term efficacy after twice daily treatment with FlutiForm HFA MDI over 12 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Ages eligible for study: 12 years and above; genders eligible for study: both; prior steroid use: steroid-requiring. Inclusion Criteria: History of asthma for at least 12 months. Documented use of inhaled corticosteriod for at least 4 weeks prior to Screening Visit Demonstrate FEV-1 of 40-80% of predicted normal values at Screening and Baseline Visit. Documented reversibility of 15% within 6 months of Screening Visit or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation). Symptoms of Asthma during Run-in. Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating and are either sterile or using acceptable methods of contraception. Must otherwise be healthy. Provide written informed consent. Wishes of minors must be respected. Exclusion Criteria: Life-threatening asthma within past year or during Run-in Period. History of systemic corticosteroid medication within 3 months before Screening Visit. History of omalizumab use within the past 6 months. History of leukotriene receptor antagonist use, e.g., montelukast, within the past week. Current evidence of history of any clinically significant disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia. Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-in Period. Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease [COPD], cystic fibrosis, bronchiectasis). Known Human Immunodeficiency Virus (HIV)-positive status. Smoking history equivalent to "10 pack years". Current smoking history within 12 months prior to Screening Visit.
Facility Information:
Facility Name
Research Site
City
Berlin
Country
Germany
Facility Name
Research Site
City
Hamburg
Country
Germany
Facility Name
Research Site
City
Mainz
Country
Germany
Facility Name
Research Site
City
Rudersdorf
Country
Germany
Facility Name
Research Site
City
Solingen
Country
Germany
Facility Name
Research Site
City
Budapest
Country
Hungary
Facility Name
Research Site
City
Deszk
Country
Hungary
Facility Name
Research Site
City
Kecskemet
Country
Hungary
Facility Name
Research Site
City
Miskolc
Country
Hungary
Facility Name
Research Site
City
Mosonmagyarovar
Country
Hungary
Facility Name
Research Site
City
Bialystok
Country
Poland
Facility Name
Research Site
City
Gdansk
Country
Poland
Facility Name
Research Site
City
Krakow
Country
Poland
Facility Name
Research Site
City
Lodz
Country
Poland
Facility Name
Research Site
City
Wroclaw
Country
Poland
Facility Name
Research Site
City
Bucharest
Country
Romania
Facility Name
Research Site
City
Birmingham
Country
United Kingdom
Facility Name
Research Site
City
Carrickfergus
Country
United Kingdom
Facility Name
Research Site
City
Chippenham
Country
United Kingdom
Facility Name
Research Site
City
Cottingham
Country
United Kingdom
Facility Name
Research Site
City
Coventry
Country
United Kingdom
Facility Name
Research Site
City
Downpatrick
Country
United Kingdom
Facility Name
Research Site
City
Heywood
Country
United Kingdom
Facility Name
Research Site
City
Manchester
Country
United Kingdom
Facility Name
Research Site
City
Sheffield
Country
United Kingdom
Facility Name
Research Site
City
Solihull
Country
United Kingdom
Facility Name
Research Site
City
Sunbury on Thames
Country
United Kingdom
Facility Name
Research Site
City
Swindon Wilts
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
23098325
Citation
Mansur AH, Kaiser K. Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma. J Aerosol Med Pulm Drug Deliv. 2013 Aug;26(4):190-9. doi: 10.1089/jamp.2012.0977. Epub 2012 Oct 25.
Results Reference
derived

Learn more about this trial

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

We'll reach out to this number within 24 hrs